RESUMO
The ability to undergo non-oxidative metabolism from ethanol to fatty acid ethyl esters (FAEEs) varies greatly among tissues and organs. To gain a greater understanding of non-oxidative ethanol metabolism to FAEE, we aimed to collect all published data on FAEE synthesis in mammalian organs and tissues to identify all tissues, organs, and enzymes that are known to, or likely possess FAEE-synthetic activity. A systematic search for relevant papers was performed and two independent reviewers examined potentially relevant abstracts (articles on FAEEs that pertain to ethanol exposure) to determine whether they met the inclusion criteria. Information on FAEE synthesis was retrieved from papers meeting the inclusion/exclusion criteria and summarized by organ/tissue/matrix examined. The systematic search through four databases yielded 78 articles that investigated FAEE synthesis by tissues, tissue fractions and cell lines, and 29 articles that attempted to purify and/or characterize the enzymes involved in FAEE synthesis. Two enzyme activities have been studied: FAEE synthase (FAEES, which conjugates ethanol and free fatty acid) and acyl-CoA: ethanol O-acyltransferase (AEAT, which conjugates ethanol and fatty acyl-CoA). Both activities are expressed by a variety of different enzymes. FAEES activity is the most widely studied and has been purified from several tissues and shown to be associated with several well-known enzymes, while the identity of enzymes possessing AEAT activity remains unknown. The organs and tissues that have been shown to synthesize FAEEs are discussed, with special emphasis on the studies that attempted to elucidate the enzymology of FAEE synthesis in those tissues.
Assuntos
Aciltransferases/metabolismo , Etanol/metabolismo , Ácidos Graxos/biossíntese , Animais , Ésteres/metabolismo , Etil-Éteres/metabolismo , Ácidos Graxos/metabolismo , Humanos , Mamíferos/metabolismo , OxirreduçãoRESUMO
The P2X7 receptor is an ATP-gated cation channel expressed by a number of cell types, including osteoblasts. Genetically modified mice with loss of P2X7 function exhibit altered bone formation. Moreover, activation of P2X7 in vitro stimulates osteoblast differentiation and matrix mineralization, although the underlying mechanisms remain unclear. Because osteogenesis is associated with enhanced cellular metabolism, our goal was to characterize the effects of nucleotides on metabolic acid production (proton efflux) by osteoblasts. The P2X7 agonist 2',3'-O-(4-benzoylbenzoyl)ATP (BzATP; 300 µM) induced dynamic membrane blebbing in MC3T3-E1 osteoblast-like cells (consistent with activation of P2X7 receptors) but did not induce cell death. Using a Cytosensor microphysiometer, we found that 9-min exposure to BzATP (300 µM) caused a dramatic increase in proton efflux from MC3T3-E1 cells (â¼2-fold), which was sustained for at least 1 h. In contrast, ATP or UTP (100 µM), which activate P2 receptors other than P2X7, failed to elicit a sustained increase in proton efflux. Specific P2X7 receptor antagonists A 438079 and A 740003 inhibited the sustained phase of the BzATP-induced response. Extracellular Ca²âº was required during P2X7 receptor stimulation for initiation of sustained proton efflux, and removal of extracellular glucose within the sustained phase abolished the elevation elicited by BzATP. In addition, inhibition of phosphatidylinositol 3-kinase blocked the maintenance but not initiation of the sustained phase. Taken together, we conclude that brief activation of P2X7 receptors on osteoblast-like cells triggers a dramatic, Ca²âº-dependent stimulation of metabolic acid production. This increase in proton efflux is sustained and dependent on glucose and phosphatidylinositol 3-kinase activity.
Assuntos
Sinalização do Cálcio/efeitos dos fármacos , Osteoblastos/efeitos dos fármacos , Fosfatidilinositol 3-Quinases/metabolismo , Agonistas do Receptor Purinérgico P2X/farmacologia , Receptores Purinérgicos P2X7/metabolismo , Trifosfato de Adenosina/metabolismo , Animais , Remodelação Óssea/efeitos dos fármacos , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Células Clonais , Inibidores Enzimáticos/farmacologia , Glucose/metabolismo , Concentração de Íons de Hidrogênio , Cinética , Ácido Láctico/metabolismo , Ligantes , Camundongos , Osteoblastos/metabolismo , Osteoblastos/patologia , Inibidores de Fosfoinositídeo-3 Quinase , Agonistas do Receptor Purinérgico P2X/química , Agonistas do Receptor Purinérgico P2X/metabolismo , Antagonistas do Receptor Purinérgico P2X/farmacologia , Receptores Purinérgicos P2X7/química , Uridina Trifosfato/metabolismoRESUMO
BACKGROUND: Meconium analysis for fatty acid ethyl esters (FAEEs) is a validated method for identifying heavy prenatal ethanol (EtOH) exposure. This study investigated whether delayed sample collection can result in false-positive test results for FAEEs because of collection of samples potentially contaminated with postnatally produced stool. METHODS: Serial excretions were prospectively collected from neonates born to nondrinking mothers to capture the transition from meconium to postnatal stool. These were analyzed for FAEEs using headspace-solid phase microextraction and gas chromatography-mass spectrometry. Experiments involving incubation of samples with glucose or EtOH were performed to explore a potential mechanism of FAEE elevation. RESULTS: A total of 136 samples were collected from 30 neonates during their first few days of life (median of 4 samples/baby over a mean period of 68.5 hours postpartum). Although the first-collected meconium sample tested negative for FAEEs in all babies, later samples tested above the 2 nmol/g positive cutoff in 19 of 30 babies. Median time to appearance of FAEE-positive samples was 59.2 hours postpartum. In vitro experiments demonstrated that FAEE levels can be further increased in late samples (likely containing postnatal stool) after incubation with glucose, and that FAEEs are readily formed in meconium in the presence of EtOH. CONCLUSIONS: Collection of samples excreted later in the postpartum period can lead to false-positive test results for FAEEs, which could be because of contamination with dietary components of postnatally produced stool and EtOH-producing microorganisms. Clinically, it is critical to collect the earliest possible excretion for determination of FAEEs to ensure that the FAEE content is representative of in utero EtOH exposure.
Assuntos
Depressores do Sistema Nervoso Central/metabolismo , Etanol/metabolismo , Ácidos Graxos/análise , Mecônio/química , Adulto , Carboidratos/química , Ésteres/análise , Reações Falso-Positivas , Fezes/química , Fezes/microbiologia , Feminino , Transtornos do Espectro Alcoólico Fetal , Cromatografia Gasosa-Espectrometria de Massas , Glucose/química , Humanos , Recém-Nascido , Lipase/análise , Gravidez , Estudos Prospectivos , Microextração em Fase SólidaRESUMO
The main objective of this study is to evaluate the clinical utility of meconium analysis for fatty acid ethyl esters as a universal screening tool intended for the detection of newborns at risk for fetal alcohol spectrum disorder. This will be accomplished by assessing the rate of voluntary participation in a nonanonymous neonatal screening program and by determining the logistics of implementing the necessary follow-up and interventions as part of routine care. Additionally, this study will determine the predictive value of fatty acid ethyl ester-positive meconium with regard to neurodevelopmental delays. This is an ongoing prospective cohort study. Written informed consent is sought from all Grey Bruce women delivering at participating birthing sites. Collected meconium samples are tested for fatty acid ethyl esters by headspace-solid-phase microextraction followed by gas chromatography-mass spectrometry. Children with positive results are followed up through an existing public health program involving regular home visits and assessments of developmental milestones by a public health nurse. These children and matched control subjects also undergo neurodevelopmental testing at 3 and 18 months of age by a clinical psychologist using Bayley Scales of Infant and Toddler Development. If delays are detected, the child is referred to diagnostic services and appropriate intervention programs. This study has been granted ethics approval and enrollment began in November 2008 at St. Joseph's Health Care in London, Ontario. The first positive case has been identified and the follow-up is currently being conducted by the public health unit. The successful completing of this study will reveal the population's willingness to participate in a neonatal screening program for prenatal alcohol exposure and determine the costs, feasibility, and utility of implementing such programs in clinical practice.
Assuntos
Alcoolismo/metabolismo , Etanol/toxicidade , Transtornos do Espectro Alcoólico Fetal/etiologia , Feto/efeitos dos fármacos , Programas de Rastreamento/métodos , Ésteres/análise , Ácidos Graxos/análise , Feminino , Transtornos do Espectro Alcoólico Fetal/metabolismo , Cromatografia Gasosa-Espectrometria de Massas , Unidades Hospitalares , Humanos , Lactente , Recém-Nascido , Londres , Mecônio/metabolismo , Ontário , Projetos Piloto , Gravidez , Cuidado Pré-Natal/legislação & jurisprudência , Desenvolvimento de ProgramasRESUMO
Very rarely therapeutic drug monitoring is evaluated for its ability to provide cost savings. A new article describes the cost-effectiveness of meconium analysis for fatty acid ethyl esters in the management of fetal alcohol spectrum disorder. This article is a summary and a critical appraisal of the article by Hopkins et al.
Assuntos
Transtornos do Espectro Alcoólico Fetal/economia , Programas de Rastreamento/economia , Triagem Neonatal/economia , Análise Custo-Benefício , Etanol/efeitos adversos , Feminino , Transtornos do Espectro Alcoólico Fetal/diagnóstico , Humanos , Recém-Nascido , Gravidez , Efeitos Tardios da Exposição Pré-Natal/diagnóstico , Fatores de RiscoRESUMO
Acute poisonings during pregnancy pose a particular challenge to health care providers because of the potential for an immediate life threat or possible life-long implications for both the mother and fetus, including teratogenicity of the poison or its antidote. We describe recent consequential exposures among pregnant women in the USA. We identified all poisoning cases involving pregnant women that were catalogued by the medical toxicology services across the 37 sites of the Toxicology Investigators Consortium (ToxIC) Registry of the American College of Medical Toxicology between January 2010 and December 2012. Of 17,529 exposure cases reported in the ToxIC Registry, 103 (0.6 %) involved pregnant women, 80 % of whom were symptomatic and about a quarter displayed a specific toxidrome. The majority of cases (n = 53; 51.5 %) involved intentional exposures, most commonly to pharmaceutical agents, followed by unintentional pharmaceutical exposures (10 %) and withdrawal syndromes (9 %). Non-opioid analgesics were the most common class of agents encountered (31 %), followed by sedative-hypnotics/muscle relaxants (18 %), opioids (17 %), anti-convulsants (10 %), and anti-depressants (10 %). Over a third of cases involved exposure to multiple substances, and 32 % involved exposure to more than one drug class. The most commonly administered antidotes were N-acetylcysteine (23 %), sodium bicarbonate (10 %), flumazenil (4 %), and physostigmine (4 %). About half of acute poisoning cases among pregnant women presenting for emergency care involved intentional exposures, mostly with over-the-counter analgesics and psychoactive medications. Clinicians should be cognizant of the unique circumstances, maternal and fetal risks, and management principles of the acutely poisoned pregnant woman.
Assuntos
Antídotos/uso terapêutico , Intoxicação/terapia , Complicações na Gravidez/terapia , Doença Aguda , Serviços Médicos de Emergência , Feminino , Humanos , Medicamentos sem Prescrição/intoxicação , Intoxicação/diagnóstico , Intoxicação/epidemiologia , Gravidez , Complicações na Gravidez/diagnóstico , Complicações na Gravidez/epidemiologia , Psicotrópicos/intoxicação , Sistema de Registros , Medição de Risco , Fatores de Risco , Resultado do Tratamento , Estados Unidos/epidemiologiaRESUMO
PURPOSE OF REVIEW: Since the first description of the foetal damage of alcohol in 1967, numerous studies have outlined different aspects of neurodevelopmental dysfunction, adversely affecting the lives of children worldwide. Although the cause of the syndrome is sorted out, the pathogenesis of brain damage is far from being clear. In contrast to children exhibiting the full facial dysmorphology, who are relatively easy to diagnose, in those presenting only with alcohol-related neurodevelopmental damage diagnosis is much more challenging due to poor specificity of the brain dysfunction. Hence, identifying the neurodevelopmental phenotype of foetal alcohol spectrum disorder (FASD) is a major challenge. RECENT FINDINGS: Recently, a behavioural phenotype of FASD has been described and validated using items from the Child Behaviour Checklist. This tool has high sensitivity and specificity in separating children with FASD from those with ADHD and from healthy controls. In parallel, a number of intervention studies show promise in improving the abilities of children and adolescents with the syndrome to cope with daily tasks and improve their quality of life. SUMMARY: The neurobehavioural screening test can facilitate screening for FASD and is an official screening tool in the FASD toolkit of the Public Health Agency of Canada. Promising new interventions may attenuate the long-term outcome of these children.
Assuntos
Transtornos do Comportamento Infantil/diagnóstico , Transtornos do Espectro Alcoólico Fetal/diagnóstico , Testes Neuropsicológicos , Adolescente , Criança , Transtornos do Comportamento Infantil/psicologia , Deficiências do Desenvolvimento/diagnóstico , Deficiências do Desenvolvimento/psicologia , Transtornos do Espectro Alcoólico Fetal/psicologia , Humanos , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
Alcohol (ethanol) consumption in pregnancy is the etiology of fetal alcohol spectrum disorder (FASD), a leading cause of congenital disability worldwide. Hence, any attempt to prevent or manage FASD must start from comprehensive understanding of alcohol consumption by women in general, and by women of reproductive years in particular. This review presents and synthesizes studies conducted worldwide on alcohol consumption by pregnant women, risk factors associated with gestational drinking, as well as doses and definitions of drinking behaviours.
Assuntos
Consumo de Bebidas Alcoólicas/epidemiologia , Transtornos do Espectro Alcoólico Fetal/epidemiologia , Consumo de Bebidas Alcoólicas/efeitos adversos , Feminino , Saúde Global , Humanos , Gravidez , Fatores de Risco , Fatores SexuaisRESUMO
Due to its wide range of deleterious effects on the unborn baby, knowledge on the disposition of ethanol in the maternal-fetal unit is critical. This review summarizes and updates the existing evidence on ethanol disposition in the mother, the placenta and the fetus, and relates them to their potential fetal effects.
Assuntos
Etanol/farmacocinética , Feto/efeitos dos fármacos , Feto/metabolismo , Troca Materno-Fetal/efeitos dos fármacos , Troca Materno-Fetal/fisiologia , Animais , Etanol/efeitos adversos , Feminino , Humanos , GravidezRESUMO
BACKGROUND: Meconium fatty acid ethyl esters (FAEE) constitute a biomarker of heavy fetal ethanol exposure. Our objective was to measure meconium FAEE in fetal sheep following daily, relatively moderate-dose ethanol exposure in late gestation, and to evaluate their utility in identifying fetal organ-system injury. METHODS: Pregnant ewes received ethanol (0.75 g/kg; nâ=â14) or saline (nâ=â8) via 1-h i.v. infusion daily during the third trimester equivalent, while additional pregnant sheep served as untreated controls (nâ=â6). The daily ethanol regimen produced similar maximal maternal and fetal plasma ethanol concentrations of 0.11-0.12 g/dL. Ewes and fetuses were euthanized shortly before term, and meconium was collected and analyzed for FAEE (ethyl palmitate, stearate, linoleate, and oleate). RESULTS: Meconium total FAEE concentration was significantly higher in ethanol-exposed fetuses compared with controls, and a positive cut-off of 0.0285 nmol total FAEE/g meconium had 93.3% sensitivity and specificity for detecting fetal ethanol exposure. When the studied animals (ethanol-exposed and controls) were classified according to meconium FAEE concentration, FAEE-positive and FAEE-negative groups frequently differed with respect to previously examined pathological endpoints, including nephron endowment, lung collagen deposition, cardiomyocyte maturation, and tropoelastin gene expression in cerebral vessels. Furthermore, in all studied animals as a group (ethanol-exposed and controls combined), meconium FAEE concentration was correlated with many of these pathological endpoints in fetal organs. CONCLUSIONS: We conclude that, in fetal sheep, meconium FAEE could serve as a biomarker of daily ethanol exposure in late gestation and could identify fetuses with subtle ethanol-induced toxic effects in various organs. This study illustrates the potential for using meconium FAEE to identify neonates at risk for dysfunction of major organs following in-utero ethanol exposure that does not result in overt physical signs of ethanol teratogenicity.
Assuntos
Biomarcadores/metabolismo , Ésteres/metabolismo , Etanol/toxicidade , Ácidos Graxos/metabolismo , Transtornos do Espectro Alcoólico Fetal/metabolismo , Mecônio/metabolismo , Animais , Feminino , Gravidez , Ovinos , Carneiro DomésticoRESUMO
Fatty acid ethyl esters (FAEEs) in meconium are validated biomarkers of heavy fetal alcohol exposure that may potentially be used clinically for identifying children at risk for alcohol-related disabilities. However, until now, FAEEs have been largely used anonymously in epidemiological studies, and by child protection authorities in need for verification of heavy alcohol use in pregnancy. Here we describe the first case of a neonate identified as part of a research study on a pilot neonatal screening program for prenatal alcohol exposure. The neonate's meconium tested high for FAEEs (52 nmol/g; positive cut-off ≥ 2 nmol/g), which prompted active follow-up of the infant's development, identifying early neurocognitive problems and allowing initiation of a remedial program.
Assuntos
Ácidos Graxos/análise , Transtornos do Espectro Alcoólico Fetal/diagnóstico , Mecônio/química , Consumo de Bebidas Alcoólicas/efeitos adversos , Consumo de Bebidas Alcoólicas/metabolismo , Biomarcadores/análise , Biomarcadores/metabolismo , Ácidos Graxos/metabolismo , Feminino , Transtornos do Espectro Alcoólico Fetal/metabolismo , Humanos , Lactente , Recém-Nascido , Mecônio/metabolismo , Triagem Neonatal/métodos , GravidezRESUMO
Meconium fatty acid ethyl esters (FAEEs) are validated biomarkers of fetal alcohol exposure. Meconium FAEE testing can potentially be used as a screen by health-care professionals to identify neonates at-risk for Fetal Alcohol Spectrum Disorder, thereby permitting diagnostic follow-up of these children and early intervention in those who develop disabilities. The purpose of this study was to assess whether women would willingly partake in a screening program of this nature. This was determined by launching a pilot screening program for prenatal alcohol exposure in a high-risk obstetric unit previously shown to have a high prevalence of FAEE-positive meconium via anonymous meconium testing. The program involved voluntary testing of meconium for FAEEs and long-term developmental follow-up of positive cases through an existing public health program. The participation rate in the screening program was significantly lower than when testing was conducted anonymously (78% vs. 95%, respectively; p < 0.05), and the positivity rate was 3% in contrast to 30% observed under anonymous conditions (p < 0.001). These low rates suggest that the majority of mothers who consumed alcohol in pregnancy refused to participate. We conclude that despite the potential benefits of such screening programs, maternal unwillingness to consent, likely due to fear, embarrassment, and guilt, may limit the effectiveness of meconium testing for population-based open screening, highlighting the need for public education and social marketing efforts for such programs to be of benefit.